Business
After a challenging year in the wake of the FDA decision on MDMA-assisted therapy for PTSD, the MAPS Board of Directors has embraced a new model of leadership, naming Betty Aldworth and Ismail Lourido Ali as co-executive directors.
The future of ibogaine therapy was a central topic at the 2025 Psychedelic Science conference, where it was endorsed by former Texas governor Rick Perry and others. Other states are following suit, but some advocates worry about possible exploitation of the plant medicine.
Although the safety status of regulated psilocybin services in Oregon has not raised alarm bells since their rollout, providers remain frustrated by the high cost of the services and the difficulty in marketing them to people who could benefit.
Has the psilocybin therapy industry peaked already in Oregon? Growth is slow, and uncertainty reigns, but safeguards seem to be working.
Entrepreneurs Nick Janicki of the float tank company True REST and Robin Arnott of the “digital psychedelic” company SoundSelf are teaming up to create centers that they say will offer clinical ketamine treatment together with prep and integration services including float tanks, music, and light technologies.
The second annual Psychedelics as Medicine Conference will gather influential researchers and policy makers in Reykjavik, Iceland for a two-day conference.
Leaders in policy, investment, community care, and media will discuss the future of psychedelics in society during a discussion entitled “Psychedelics: Agents of Change” at NeueHouse Madison Square in New York City.
Mindstate Design Labs has received approval for a Phase 1 clinical trial to investigate the use of its formulation of 5-MeO-MiPT which it hopes to combine with other drugs to target precise serotonin receptors and create future psychotropic therapies.
Lykos Therapeutics CEO Amy Emerson is being replaced by interim CEO Michael Mullette in a company restructuring that began after the FDA’s rejection of Lykos’ application for MDMA-Assisted Therapy for PTSD.
In the wake of the FDA’s rejection of its proposed MDMA-assisted therapy for PTSD, Lykos Therapeutics laid off approximately 100 employees and appointed new leadership while the MAPS nonprofit cut 33% of its workforce.
